Literature DB >> 27486131

Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.

Karin K Shih1, Carla Hajj2, Marisa Kollmeier2, Melissa K Frey3, Yukio Sonoda4, Nadeem R Abu-Rustum4, Kaled M Alektiar5.   

Abstract

OBJECTIVE: The purpose was to determine the potential impact of IMRT on the rate of bowel obstruction (BO), in patients with gynecologic malignancies undergoing postoperative pelvic RT.
METHODS: We performed a retrospective review of all patients with endometrial or cervical cancer who received postoperative pelvic RT at our institution from 2000 to 2012. Patients who received definitive or palliative RT, or those with BO due to disease progression, were excluded. Standard two-sided statistical tests were used to evaluate for associated risk factors. Kaplan-Meier, Log rank and Cox proportional hazards regression analysis tests were performed for actuarial analysis.
RESULTS: A total of 224 patients were identified, 120 (54%) received postoperative pelvic IMRT and 104 (46%) 3-dimentional (3-D) RT. Median follow-up time was 67months. BO was grade 1 (asymptomatic) in 2/228 (0.9%), grade 2 (conservative management) in 4 (1.8%), and grade 3≥ in 4 (1.8%). Overall, the 5-year actuarial rate of BO was 4.8%. The 5-year rate of BO in the IMRT group was 0.9% compared to 9.3% for 3-D RT (p=0.006). Patients with BMI≥30kg/m(2) were less likely to develop BO (2.6% vs. 8.3; p=0.03). On multivariate analysis, only IMRT retained its significance as an independent predictor of less BO (p=0.022).
CONCLUSIONS: The use of postoperative IMRT for cervical and endometrial cancer was associated with significant reduction in the rate of bowel obstruction. This difference maintained its statistical significance on multivariate analysis. Such finding if confirmed by others will help further solidify the benefit of IMRT in gynecologic cancers.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bowel obstruction; Cervical cancer; Endometrial cancer; IMRT

Mesh:

Year:  2016        PMID: 27486131      PMCID: PMC5031532          DOI: 10.1016/j.ygyno.2016.07.116

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.

Authors:  L Andy Chen; Jaewhan Kim; Kenneth Boucher; Breanne Terakedis; Britney Williams; Nancy A Nickman; David K Gaffney
Journal:  Gynecol Oncol       Date:  2015-01-03       Impact factor: 5.482

2.  Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.

Authors:  Petra Georg; Dietmar Georg; Martin Hillbrand; Christian Kirisits; Richard Pötter
Journal:  Radiother Oncol       Date:  2006-06-12       Impact factor: 6.280

3.  The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy.

Authors:  Nora T Kizer; Premal H Thaker; Feng Gao; Israel Zighelboim; Matthew A Powell; Janet S Rader; David G Mutch; Perry W Grigsby
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

4.  Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study.

Authors:  Vivian E von Gruenigen; Chunqiao Tian; Heidi Frasure; Steven Waggoner; Henry Keys; Richard R Barakat
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

5.  Long-term outcomes using adjuvant pelvic intensity modulated radiation therapy (IMRT) for endometrial carcinoma.

Authors:  Siping He; Beant S Gill; Dwight E Heron; Joseph L Kelley; Paniti Sukumvanich; Alexander B Olawaiye; Robert P Edwards; John Comerci; Sushil Beriwal
Journal:  Pract Radiat Oncol       Date:  2016-06-15

6.  Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.

Authors:  Michael R Folkert; Karin K Shih; Nadeem R Abu-Rustum; Elizabeth Jewell; Marisa A Kollmeier; Vicky Makker; Richard R Barakat; Kaled M Alektiar
Journal:  Gynecol Oncol       Date:  2012-11-15       Impact factor: 5.482

7.  Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies.

Authors:  Mohit Kasibhatla; Robert W Clough; Gustavo S Montana; James R Oleson; Kim Light; Beverley A Steffey; Ellen L Jones
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-20       Impact factor: 7.038

8.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

9.  Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer.

Authors:  Karin K Shih; Sarah A Milgrom; Nadeem R Abu-Rustum; Marisa A Kollmeier; Ginger J Gardner; William P Tew; Richard R Barakat; Kaled M Alektiar
Journal:  Gynecol Oncol       Date:  2012-11-20       Impact factor: 5.482

10.  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2.

Authors:  Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  3 in total

1.  NRG Oncology/RTOG Consensus Guidelines for Delineation of Clinical Target Volume for Intensity Modulated Pelvic Radiation Therapy in Postoperative Treatment of Endometrial and Cervical Cancer: An Update.

Authors:  William Small; Walter R Bosch; Mathew M Harkenrider; Jonathan B Strauss; Nadeem Abu-Rustum; Kevin V Albuquerque; Sushil Beriwal; Carien L Creutzberg; Patricia J Eifel; Beth A Erickson; Anthony W Fyles; Courtney L Hentz; Anuja Jhingran; Ann H Klopp; Charles A Kunos; Loren K Mell; Lorraine Portelance; Melanie E Powell; Akila N Viswanathan; Joseph H Yacoub; Catheryn M Yashar; Kathryn A Winter; David K Gaffney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-06       Impact factor: 7.038

2.  Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.

Authors:  Junzo Chino; Christina M Annunziata; Sushil Beriwal; Lisa Bradfield; Beth A Erickson; Emma C Fields; KathrynJane Fitch; Matthew M Harkenrider; Christine H Holschneider; Mitchell Kamrava; Eric Leung; Lilie L Lin; Jyoti S Mayadev; Marc Morcos; Chika Nwachukwu; Daniel Petereit; Akila N Viswanathan
Journal:  Pract Radiat Oncol       Date:  2020-05-18

3.  Dosimetric comparison of three-dimensional conformal radiotherapy versus volumetric-arc radiotherapy in cervical cancer treatment: applying the central-shielding principle to modern technology.

Authors:  Tomoaki Tamaki; Ryuta Hirai; Mitsunobu Igari; Yu Kumazaki; Shin-Ei Noda; Yoshiyuki Suzuki; Shingo Kato
Journal:  J Radiat Res       Date:  2018-09-01       Impact factor: 2.724

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.